Popular Articles

Confirmation Of High Efficacy Of HPV Vaccine Against Precancerous Cervical Lesions And Protective Effect Of Vaccination Programs
The findings of the PATRICIA study are reported in an article Online First and in a future edition of The Lancet. It shows that the HPV-16/18 AS04-adjuvanted vaccine (GlaxoSmithKline) has high efficacy against the precancerous cervical lesions that can eventually lead to cervical cancer. There is confirmation that the vaccine also shows cross-protective efficacy against other oncogenic (that cause cancer) Human Papillomavirus (HPV) types closely related to HPV-16/18. In addition, it also shows efficacy in the cohorts relevant to universal mass vaccination and catch-up programs. The article is written by Dr Jorma Paavonen, of the University of Helsinki, Finland, and collaborators.

The Dangers Of Stimulant Chewing Gum
A case report written by Dr Francesco Natale and his colleagues, from the Second University of Naples and Monaldi Hospital, Naples, Italy, reports on the dangers of stimulant chewing gums containing caffeine. The report published in this week÷´s edition of The Lancet describes the story of a teenage boy hospitalized after excessive consumption of this type of product. The authors warn about the high risks of stimulant chewing gums that are widely available to children.
News of the day
ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data In Crohn's Disease To Be Featured In Oral Presentation At 2009 Digestive Disease Week
ChemoCentryx, Inc., announced that data from the company"s PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn"s disease Trial) Phase II/III clinical trial of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn"s disease will be presented in an oral session at the upcoming 2009 Digestive Disease Week (DDW) meeting. Traficet-EN is an orally-available small molecule drug that controls the inappropriate immune system response underlying inflammatory bowel diseases by blocking the CCR9 chemokine receptor. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn"s disease and other inflammatory disorders of the gastrointestinal system. DDW 2009 will be held on May 30 - June 4, 2009, at McCormick Place in Chicago, Illinois.
Oncology

'Hijacking Mechanism' Of HIV-1' Pinpointed By McGill/JGH Researchers

Researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal"s Jewish General Hospital - along with colleagues at the University of Manitoba and the University of British Columbia - may have found a chink in the armour of the human immunodeficiency virus type 1 (HIV-1), the microorganism which causes AIDS. They have pinpointed the key cellular machinery co-opted by HIV-1 to hijack the human cell for its own benefit. Their study was published in May in the Journal of Biological Chemistry. Once a cell is infected with HIV-1, activation of the virus"s gene generates a large HIV-1 RNA molecule known as the RNA genome. This is then transported from the cell nucleus to the inner surface of the plasma membrane. The RNA genome can produce both structural proteins and enzymes, but once it arrives at the plasma membrane it can also assemble into new copies of the virus that actually bud out of the cell. Dr. Andrew J. Mouland and his colleagues have discovered how the RNA genome gets transported - or trafficked - from the nucleus to the plasma membrane. "There is a highway inside the human cell," explained Dr. Mouland, Associate Professor at McGill"s Departments of Medicine and Microbiology and Immunology and head of the HIV-1 RNA Trafficking Laboratory at the Lady Davis Institute. "When you drive your car to Toronto you"re "trafficking" the items in your trunk. Similarly, what we have shown is that HIV-1 commandeers the host cell"s endosomal machinery to traffic its structural proteins and RNA genome. Imagine that it"s essentially jumping on board for the ride and directing it to where it needs to go. This trafficking can occur very fast in cells; so this is how these key components of HIV-1 so efficiently get to the plasma membrane, where the virus can begin to assemble. "The RNA genome is critical, because if it doesn"t get trafficked to the right place at the plasma membrane, the virus will not be infectious," he explained. This discovery is extremely exciting, Dr. Mouland said, because now that researchers understand a little more about how the cell"s transport machinery is hijacked by HIV-1, they have hopes that they can now begin to devise strategies to block the process. This work is substantiated by a co-submitted manuscript from the group of ç‰douard Bertrand at the Institut de gçİnçİtique molçİculaire de Montpellier, Centre national de recherche scientifique. The Bertrand group will publish its work in the same journal in June, 2009. Mark Shainblum McGill University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):